Citadel Advisors
CLVS

Citadel Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Citadel Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-183,700
Closed -$219K – 15849
2022
Q3 		$219K Sell
183,700
-183,900
-50% -$287K ﹤0.01% 10232
2022
Q2 		$662K Buy
367,600
+122,200
+50% +$180K ﹤0.01% 8015
2022
Q1 		$496K Buy
245,400
+50,900
+26% +$100K ﹤0.01% 9427
2021
Q4 		$527K Sell
194,500
-78,300
-29% -$289K ﹤0.01% 9576
2021
Q3 		$1.22M Sell
272,800
-234,100
-46% -$1.13M ﹤0.01% 7641
2021
Q2 		$2.94M Buy
506,900
+8,300
+2% +$48.6K ﹤0.01% 5654
2021
Q1 		$3.5M Buy
498,600
+259,700
+109% +$1.74M ﹤0.01% 5071
2020
Q4 		$1.15M Sell
238,900
-38,400
-14% -$194K ﹤0.01% 6519
2020
Q3 		$1.62M Buy
277,300
+52,200
+23% +$312K ﹤0.01% 5130
2020
Q2 		$1.52M Buy
225,100
+49,300
+28% +$373K ﹤0.01% 5047
2020
Q1 		$1.12M Sell
175,800
-77,700
-31% -$623K ﹤0.01% 5138
2019
Q4 		$2.64M Buy
253,500
+162,700
+179% +$1.18M ﹤0.01% 3983
2019
Q3 		$357K Buy
90,800
+10,600
+13% +$85.7K ﹤0.01% 7302
2019
Q2 		$1.19M Sell
80,200
-35,600
-31% -$643K ﹤0.01% 5412
2019
Q1 		$2.87M Sell
115,800
-47,100
-29% -$1.18M ﹤0.01% 3835
2018
Q4 		$2.93M Buy
162,900
+49,600
+44% +$1.01M ﹤0.01% 3553
2018
Q3 		$3.33M Buy
113,300
+23,300
+26% +$902K ﹤0.01% 3567
2018
Q2 		$4.09M Buy
90,000
+6,000
+7% +$292K ﹤0.01% 3037
2018
Q1 		$4.43M Buy
84,000
+7,600
+10% +$443K ﹤0.01% 2594
2017
Q4 		$5.2M Buy
76,400
+3,200
+4% +$224K ﹤0.01% 2436
2017
Q3 		$6.03M Sell
73,200
-700
-0.9% -$55.5K ﹤0.01% 2106
2017
Q2 		$6.92M Buy
73,900
+20,600
+39% +$1.26M 0.01% 1781
2017
Q1 		$3.39M Buy
53,300
+11,600
+28% +$705K ﹤0.01% 2455
2016
Q4 		$1.85M Sell
41,700
-26,800
-39% -$943K ﹤0.01% 3039
2016
Q3 		$2.47M Buy
68,500
+49,200
+255% +$1.06M ﹤0.01% 2730
2016
Q2 		$265K Sell
19,300
-9,100
-32% -$133K ﹤0.01% 5408
2016
Q1 		$545K Sell
28,400
-500
-2% -$10.6K ﹤0.01% 4290
2015
Q4 		$1.01M Sell
28,900
-11,400
-28% -$735K ﹤0.01% 3549
2015
Q3 		$3.71M Buy
40,300
+8,300
+26% +$718K ﹤0.01% 2246
2015
Q2 		$2.81M Buy
32,000
+11,300
+55% +$967K ﹤0.01% 2662
2015
Q1 		$1.54M Sell
20,700
-1,900
-8% -$134K ﹤0.01% 3407
2014
Q4 		$1.27M Sell
22,600
-1,700
-7% -$89.3K ﹤0.01% 3462
2014
Q3 		$1.1M Buy
24,300
+3,100
+15% +$130K ﹤0.01% 3586
2014
Q2 		$878K Sell
21,200
-2,600
-11% -$134K ﹤0.01% 3677
2014
Q1 		$1.65M Buy
23,800
+15,000
+170% +$1.1M ﹤0.01% 2851
2013
Q4 		$530K Buy
+8,800
New +$479K ﹤0.01% 3956

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citadel Advisors's CLVS Position: Q4 2022 in Review

Citadel Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 129,979 shares — an estimated $155K sold.

Citadel Advisors first reported a position in CLVS in Q2 2013 and held it in 34 quarters. The position peaked at $112M in Q3 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Citadel Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 129,979 Clovis Oncology, Inc. shares in Q4 2022, an estimated $155K.
  • Citadel Advisors first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 34 quarters.
  • Citadel Advisors's Clovis Oncology, Inc. position peaked at $112M in Q3 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.